Final Planned Joint Analysis of Overall Survival from NSABP-B-31 and NCCTG-N9831
Romond E et al. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. San Antonio Breast Cancer Symposium 2012;Abstract S5-5.
Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.
|